OmniAb (NASDAQ:OABIW – Get Free Report) will likely be announcing its results after the market closes on Thursday, August 6th. Analysts expect OmniAb to post earnings of ($0.12) per share and revenue of $4.6930 million for the quarter.
OmniAb Price Performance
NASDAQ OABIW opened at $0.06 on Thursday. OmniAb has a 12 month low of $0.04 and a 12 month high of $0.29. The stock has a 50 day moving average of $0.09 and a 200-day moving average of $0.09.
OmniAb Company Profile
OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.
Read More
- Five stocks we like better than OmniAb
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
